Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Morphosys Ag ADR
(NQ:
MOR
)
18.64
-0.05 (-0.27%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Morphosys Ag ADR
< Previous
1
2
3
4
Next >
MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
April 16, 2023
From
Incyte and MorphoSys U.S. Inc.
Via
Business Wire
MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 15, 2023
From
MorphoSys AG
Via
Business Wire
Invitation to MorphoSys' Full Year Results 2022 Conference Call on March 16, 2023
March 09, 2023
Via
ACCESSWIRE
MorphoSys Stops Work and Operations on Pre-Clinical Research Programs
March 02, 2023
Via
ACCESSWIRE
MorphoSys AG: Financial Calendar 2023
November 28, 2022
Via
ACCESSWIRE
MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
November 14, 2022
Via
ACCESSWIRE
Invitation to MorphoSys’ Third Quarter and First Nine Months 2022 Results Conference Call on November 17, 2022
November 10, 2022
Via
ACCESSWIRE
Ad hoc: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs and Reduces Workforce at its Germany Headquarters
March 02, 2023
Via
ACCESSWIRE
MorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024
January 09, 2023
Via
ACCESSWIRE
MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
January 05, 2023
Via
ACCESSWIRE
MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results
November 16, 2022
From
MorphoSys AG
Via
Business Wire
MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
October 21, 2022
Via
ACCESSWIRE
MorphoSys AG: Invitation to MorphoSys' Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022
July 28, 2022
Via
ACCESSWIRE
MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
July 26, 2022
Via
ACCESSWIRE
MorphoSys to Share New Data on Pelabresib and Monjuvi(R) (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting
November 03, 2022
Via
ACCESSWIRE
MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors
October 27, 2022
Via
ACCESSWIRE
GSK, MorphoSys' Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis
October 27, 2022
Via
ACCESSWIRE
MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results
August 03, 2022
From
MorphoSys AG
Via
Business Wire
Devon Energy Produces A Record Quarter, Dividend Raised By 22%
August 02, 2022
Devon Energy produced another record quarter of profits, as higher volumes and prices provided significant tailwinds to results.
Via
MarketBeat
MorphoSys AG: Invitation to MorphoSys' Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022
July 28, 2022
Conference Call Alert
From
MorphoSys AG
Via
AccessWire
MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
July 26, 2022
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / July 26, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today reported preliminary U.S. net product sales of Monjuvi® (tafasitamab-cxix) for the second quarter 2022...
From
MorphoSys AG
Via
AccessWire
MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
July 26, 2022
Via
ACCESSWIRE
MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
July 26, 2022
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014
From
MorphoSys AG
Via
AccessWire
MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210
June 14, 2022
From
MorphoSys AG
Via
Business Wire
MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022
June 10, 2022
From
MorphoSys
Via
Business Wire
MorphoSys AG Reports Outcome of Annual General Meeting 2022
May 18, 2022
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 18, 2022 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) announced today that its shareholders approved all resolutions proposed by the Company´s Management and...
From
MorphoSys AG
Via
AccessWire
MorphoSys to Present New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) at the 2022 European Hematology Association (EHA) and American Society of Clinical Oncology (ASCO) Annual Meetings
May 12, 2022
From
MorphoSys
Via
Business Wire
MorphoSys AG Reports First Quarter 2022 Financial Results
May 04, 2022
From
MorphoSys AG
Via
Business Wire
Invitation to MorphoSys' First Quarter 2022 Financial Results Conference Call on May 5, 2022
April 28, 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.
From
MorphoSys AG
Via
AccessWire
MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL
March 22, 2022
MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell...
From
MorphoSys AG
Via
AccessWire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.